The ARL1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa host cell line. This product consists of a heterogeneous pool of HeLa cells in which the ARL1 gene has been disrupted using CRISPR/Cas9 technology, generating a loss-of-function model system. As polyclonal knockout cells, they provide a population-level representation of ARL1 deficiency, allowing researchers to assess general knockout effects without clonal isolation artifacts. The cells are supplied as a ready-to-use reagent for advanced biomedical studies.
HeLa is an immortalized human cervical adenocarcinoma cell line with an epithelial morphology, originally derived from a cervical carcinoma patient. As one of the most widely utilized cell lines in biomedical research, HeLa cells serve as a versatile platform for investigating fundamental processes such as cell cycle regulation, signal transduction, and intracellular trafficking. Their robust proliferation and well-characterized genomics make them particularly suitable for CRISPR-based gene editing and subsequent phenotypic analysis.
ARL1 encodes a small GTPase that belongs to the ARF family, primarily localized to the trans-Golgi network. It cycles between an inactive GDP-bound and an active GTP-bound conformation, regulated by upstream ARF-specific guanine nucleotide exchange factors (ARF-GEFs) and phosphoinositides. Upon activation, ARL1 interacts with a network of downstream effectors including golgin-97 (GOLGA1), golgin-245 (GOLGA4), GM130 (GOLGA2), and p115 (USO1). These interactions facilitate vesicle tethering and membrane fusion events. Furthermore, ARL1 coordinates with the GARP (Golgi-associated retrograde protein) complex and COPI coatomer to maintain Golgi ribbon integrity and govern cargo sorting in the secretory pathway. The mechanistic cycle of ARL1 is integral to Golgi homeostasis and membrane trafficking dynamics.
Disruption of ARL1 in HeLa cells provides a powerful tool to examine Golgi-dependent processes in an epithelial cancer background. HeLa cells exhibit active secretion and robust Golgi organization, and ARL1 knockout leads to Golgi fragmentation, altered glycosylation, and impaired trafficking of plasma membrane proteins. This model is particularly relevant for cancer research, as Golgi dysfunction is implicated in tumor progression, metastasis, and resistance to chemotherapeutics. Additionally, the HeLa cell line??s susceptibility to transfection and gene editing enables combinatorial studies, such as rescue experiments with wild-type or mutant ARL1 constructs, to dissect structure?Cfunction relationships.
Typical research applications include immunofluorescence microscopy to visualize Golgi markers like GM130 and golgin-97, western blotting to assess ARL1 levels and effector recruitment, and GTPase activity assays using pull-down methods. The cells are also amenable to co-immunoprecipitation to detect ARL1?Cgolgin interactions, live-cell imaging of VSVG-GFP trafficking to measure secretion rates, and drug sensitivity screens targeting Golgi-disrupting agents. Furthermore, RT-qPCR can evaluate transcriptional changes in ARF-dependent pathways. This knockout cell product is thus an essential resource for laboratories investigating Golgi biology, intracellular trafficking, and cancer cell signaling. For further inquiries, please contact Ascent Research.
